Search

Author/Creator Raynaud, F.

1. 343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). (September 2015)

Authors:
Michalarea, V.; Lopez, J.; Lorente, D.; Carreira, S.; Hassam, H.; Parmar, M.; Turner, A.; Hall, E.; Fandos, S. Serrano; Decordova, S.; Swales, K.; Ruddle, R.; Raynaud, F.; Tunariu, N.; Stephens, C.M.; Molife, L.R.; Banerji, U.; Plummer, R.; Bono, J. De; Yap, T.A.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S68
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Improved binding affinity and pharmacokinetics enables sustained degradation of BCL6 in vivo. (October 2022)

Authors:
Harnden, A.; Huckvale, R.; Cheung, K.M.; Davis, O.; Pierrat, O.; Talbot, R.; Box, G.; Bright, M.; Akpinar, A.; Miller, D.; Hayes, A.; Gunnell, E.; Le Bihan, Y.V.; Burke, R.; Kirkin, V.; Van Montfort, R.; Raynaud, F.; Rossanese, O.; Bellenie, B.; Hoelder, S.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S104
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Investigating the effects of ERAP1 inhibition on antigen presentation and the tumour immune response. (October 2022)

Authors:
Margarido, A.; Whitton, B.; Arwert, E.; Cheeseman, M.; Kalusa, A.; Davison, G.; Salimraj, R.; Pierrat, O.; Richards, M.; dos Santos Costa, H.; Meister, P.; Hayes, A.; Reeves, E.; James, E.; Burke, R.; Raynaud, F.; Van Montfort, R.; Choudhary, J.; Rossanese, O.; Newton, G.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S126
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search